{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:20:29Z","timestamp":1787642429080,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10549-026-08056-7","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:41:25Z","timestamp":1786624885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of menopausal status on the efficacy of adjuvant CDK4\/6 inhibitors in hormone receptor\u2013positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials"],"prefix":"10.1007","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-372X","authenticated-orcid":false,"given":"Uri","family":"Bender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Ronan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Aljuhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Savill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"8056_CR1","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Female Breast Cancer Subtypes. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html"},{"issue":"9793","key":"8056_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771\u2013784","journal-title":"Lancet"},{"issue":"25","key":"8056_CR3","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL et al (2021) 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 385(25):2336\u20132347","journal-title":"N Engl J Med"},{"issue":"23","key":"8056_CR4","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.2016.71.4147","volume":"35","author":"JL Blum","year":"2017","unstructured":"Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr., Jacobs SA, Robert NJ, Hopkins JO, O\u2019Shaughnessy JA, Dang CT et al (2017) Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06\u2013090, NSABP B-46-I\/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 35(23):2647\u20132655","journal-title":"J Clin Oncol"},{"issue":"19","key":"8056_CR5","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M et al (2017) 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 377(19):1836\u20131846","journal-title":"N Engl J Med"},{"issue":"9","key":"8056_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M (2024) Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther 31(9):1283\u20131291","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"8056_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.annonc.2025.10.003","volume":"37","author":"EL Mayer","year":"2026","unstructured":"Mayer EL, Hlauschek D, Gnant M, O\u2019Brien PJ, Bellet-Ezquerra M, Goetz MP, Ruiz-Borrego M, Chan A, Clifton K, Egle D et al (2026) Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42\/AFT-05\/PrE0109\/BIG-14-13). Ann Oncol 37(2):271\u2013277","journal-title":"Ann Oncol"},{"issue":"14","key":"8056_CR8","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl S, Marm\u00e9 F, Martin M, Untch M, Bonnefoi H, Kim S-B, Bear H, McCarthy N, Oliv\u00e9 MM, Gelmon K et al (2021) Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer\u2014The Penelope-B Trial. J Clin Oncol 39(14):1518\u20131530","journal-title":"J Clin Oncol"},{"issue":"34","key":"8056_CR9","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E et al (2020) Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 38(34):3987\u20133998","journal-title":"J Clin Oncol"},{"issue":"12","key":"8056_CR10","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang C-S, Fasching PA, Crown J et al (2024) Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 390(12):1080\u20131091","journal-title":"N Engl J Med"},{"key":"8056_CR11","doi-asserted-by":"publisher","first-page":"104449","DOI":"10.1016\/j.breast.2025.104449","volume":"81","author":"MJ Lee","year":"2025","unstructured":"Lee MJ, Jung JJ, Cheun JH, Kang E, Kim HK, Lee HB, Moon HG, Han W (2025) Comparison of oncological outcomes of premenopausal with ovarian function suppression versus postmenopausal women in ER+\/HER2- breast cancer. Breast 81:104449","journal-title":"Breast"},{"issue":"16suppl","key":"8056_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1200\/JCO.2024.42.16_suppl.505","volume":"42","author":"K Kalinsky","year":"2024","unstructured":"Kalinsky K, Barlow WE, Pathak HB, Gralow JR, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL et al (2024) Correlation of serum anti-M\u00fcllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). J Clin Oncol 42(16suppl):505\u2013505","journal-title":"J Clin Oncol"},{"issue":"10001","key":"8056_CR13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Aromatase inhibitors versus","year":"2015","unstructured":"Aromatase inhibitors versus (2015) tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341\u20131352","journal-title":"Lancet"},{"issue":"2","key":"8056_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","volume":"379","author":"PA Francis","year":"2018","unstructured":"Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, L\u00e1ng I, G\u00f3mez HL, Tondini C, Ciruelos E, Burstein HJ et al (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379(2):122\u2013137","journal-title":"N Engl J Med"},{"key":"8056_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"1","key":"8056_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.maturitas.2010.04.015","volume":"67","author":"AI Phipps","year":"2010","unstructured":"Phipps AI, Ichikawa L, Bowles EJ, Carney PA, Kerlikowske K, Miglioretti DL, Buist DS (2010) Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60\u201366","journal-title":"Maturitas"},{"key":"8056_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"8056_CR18","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JPT, Thomas J (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database of Systematic Reviews","DOI":"10.1002\/14651858.ED000142"},{"issue":"12","key":"8056_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/0895-4356(90)90093-5","volume":"43","author":"B Burnand","year":"1990","unstructured":"Burnand B, Kernan WN, Feinstein AR (1990) Indexes and boundaries for quantitative significance in statistical decisions. J Clin Epidemiol 43(12):1273\u20131284","journal-title":"J Clin Epidemiol"},{"issue":"7305","key":"8056_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","volume":"323","author":"JJ Deeks","year":"2001","unstructured":"Deeks JJ (2001) Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 323(7305):157\u2013162","journal-title":"BMJ"},{"issue":"2","key":"8056_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","volume":"22","author":"EL Mayer","year":"2021","unstructured":"Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G et al (2021) Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 22(2):212\u2013222","journal-title":"Lancet Oncol"},{"issue":"2","key":"8056_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","volume":"37","author":"S Johnston","year":"2026","unstructured":"Johnston S, Martin M, O\u2019Shaughnessy J, Hegg R, Tolaney SM, Guarneri V, Del Mastro L, Campone M, Sohn J, Boyle F et al (2026) Overall survival with abemaciclib in early breast cancer\u2009<\u2009sup>\u2606. Ann Oncol 37(2):155\u2013165","journal-title":"Ann Oncol"},{"key":"8056_CR23","doi-asserted-by":"crossref","unstructured":"Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B et al (2025) Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival\u2009<\u2009sup>\u2606. ESMO Open 10(11)","DOI":"10.1016\/j.esmoop.2025.105858"},{"issue":"11","key":"8056_CR24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1200\/JCO.21.02742","volume":"40","author":"M Royce","year":"2022","unstructured":"Royce M, Osgood C, Mulkey F, Bloomquist E, Pierce WF, Roy A, Kalavar S, Ghosh S, Philip R, Rizvi F et al (2022) FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. J Clin Oncol 40(11):1155\u20131162","journal-title":"J Clin Oncol"},{"key":"8056_CR25","unstructured":"FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer. https:\/\/tinyurl.com\/njts3tvy"},{"key":"8056_CR26","unstructured":"Health Canada approves Novartis' KISQALI\u00ae for HR+\/HER2- early breast cancer patients at high risk of recurrence"},{"key":"8056_CR27","unstructured":"Regulatory Decision Summary Verzenio (abemaciclib). https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS1714680266149"},{"issue":"1","key":"8056_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-023-00560-z","volume":"9","author":"G Curigliano","year":"2023","unstructured":"Curigliano G, Dent R, Llombart-Cussac A, Pegram M, Pusztai L, Turner N, Viale G (2023) Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+\/HER2\u2013 breast cancer. npj Breast Cancer 9(1):56","journal-title":"npj Breast Cancer"},{"issue":"7","key":"8056_CR29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.22.01064","volume":"41","author":"O Pagani","year":"2023","unstructured":"Pagani O, Walley BA, Fleming GF, Colleoni M, L\u00e1ng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM et al (2023) Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol 41(7):1376\u20131382","journal-title":"J Clin Oncol"},{"issue":"3","key":"8056_CR30","doi-asserted-by":"publisher","first-page":"e520488","DOI":"10.1200\/EDBK-26-520488","volume":"46","author":"E Amir","year":"2026","unstructured":"Amir E, Kristoff T, Blaha C, Bender U, Kalinsky K, Cobain E (2026) Navigating Treatment Decisions in Early-Stage Hormone Receptor\u2013Positive Breast Cancer. Am Soc Clin Oncol Educational Book 46(3):e520488","journal-title":"Am Soc Clin Oncol Educational Book"},{"issue":"4","key":"8056_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.annonc.2023.01.009","volume":"34","author":"SJ Luen","year":"2023","unstructured":"Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell\u2019Orto P, Biasi O, Degasperi A, Brown LC, L\u00e1ng I et al (2023) Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann Oncol 34(4):397\u2013409","journal-title":"Ann Oncol"},{"key":"8056_CR32","doi-asserted-by":"publisher","first-page":"114192","DOI":"10.1016\/j.ejca.2024.114192","volume":"207","author":"A Haslam","year":"2024","unstructured":"Haslam A, Ranganathan S, Prasad V, Olivier T (2024) CDK4\/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. Eur J Cancer 207:114192","journal-title":"Eur J Cancer"},{"issue":"22","key":"8056_CR33","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO-24-02683","volume":"43","author":"IF Tannock","year":"2025","unstructured":"Tannock IF, Khan QJ, Fojo T (2025) Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4\/6 Inhibitor. J Clin Oncol 43(22):2456\u20132460","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08056-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:49:21Z","timestamp":1787640561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08056-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8056"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08056-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as this study is a meta-analysis of previously published aggregate data.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Eitan Amir reports honoraria from Seagen, Gilead Sciences, Pfizer, AstraZeneca, and Novartis. He has also served in a consulting or advisory role for AstraZeneca and Novartis.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"43"}}